The development of cisplatin resistance by the cancer cell is one of the major problems in treating patients with cisplatin chemotherapy. The defective accumulation of cisplatin has emerged as a salient feature of cisplatin resistance. Unfortunately, there is little information about the mechanisms of cisplatin resistance in breast cancer. The objective of this investigation is to determine the relationship between a terbium binding protein and the accumulation of cisplatin in cisplatin-sensitive and cisplatin-resistant human breast cancer cells. More specifically, the proposed research will determine whether terbium affects the accumulation and cytotoxicity of cisplatin in breast cancer cells. The proposed research also intends to determine whether the number of terbium binding sites and/or the terbium receptor affinity of cisplatin correlates with 1) the cytotoxicity of cisplatin and/or 2) the accumulation of cisplatin in sensitive and resistant breast cancer cell pairs. Time-resolved intensities of terbium phosphorescence will be used to obtain equilibrium binding constants for the receptor binding of cisplatin and terbium in dissociated cell suspensions. The amount of cisplatin taken up by the cells in culture will be measured via atomic absorption spectrophotometry. The cytotoxicity of cisplatin will be determined by the monolayer colony assay. The hypothesis of this proposal is that the terbium receptor plays a central role in the accumulation of cisplatin in breast cancer cells. If our results are encouraging, we will attempt to predict the development of cisplatin resistance in fresh human tumor specimens, based on the receptor binding of cisplatin and terbium.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Popa, Laurentiu S; Hewitt, Angela L; Ebner, Timothy J (2013) Purkinje cell simple spike discharge encodes error signals consistent with a forward internal model. Cerebellum 12:331-3
Fuller, T L; Canada, R G (1999) Enhancement of cisplatin cytotoxicity by terbium in cisplatin-resistant MDA/CH human breast cancer cells. Cancer Chemother Pharmacol 44:249-52
Canada, R G; Paltoo, D N (1998) Binding of terbium and cisplatin to C13* human ovarian cancer cells using time-resolved terbium luminescence. Biochim Biophys Acta 1448:85-98
Paltoo, D N; Canada, R G (1998) Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma. Cancer Biochem Biophys 16:213-27
Ting, P; Cushenberry, P A; Friedman, T C et al. (1997) Enhanced brain opioid receptor activity precedes blood-brain barrier disruption. Acta Neurochir Suppl 70:250-3
Mack, K M; Canada, R G; Andrews, P A (1997) The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 39:217-22
Dennis, G C; Dehkordi, O; Millis, R M et al. (1996) Monitoring of median nerve somatosensory evoked potentials during cervical spinal cord decompression. J Clin Neurophysiol 13:51-9
Canada, R G; Andrews, P A; Mack, K M et al. (1995) The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta 1267:25-30
Ting, P; Xu, S; Krumins, S (1994) Endogenous opioid system activity following temporary focal cerebral ischemia. Acta Neurochir Suppl (Wien) 60:253-6
Canada, R G (1993) Calcium receptor binding of cisplatin and terbium in human breast tumor cells after hyperthermia. Radiat Res 133:170-5